HER2‐positive BC patients often benefit from targeted therapies like trastuzumab; however, the presence of p66Shc may impact treatment efficacy due to its association with aggressive tumour behaviour and potential resistance mechanisms [89]. The gene discussed is ERBB2; the disease is breast cancer.